AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03529500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva flow rate
Description: Samples of non-stimulated saliva were collected from the participants for five minutes using two aspirator tubes connected to a 15-ml Falcon tube. One aspirator tube was positioned under the child's tongue and the other was attached to the aspirator device. After five minutes, the amount of saliva was measured for the determination of salivary flow. Collections were performed between 9 and 11 am and the time of the last meal was recorded. At least a one-hour interval was required between the last meal and the collection of the saliva sample. The volume of saliva was measured. The salivary flow volume was calculated and expressed as ml/min. The following categories were considered in the analysis of salivary flow: \< 0.1 ml/min = xerostomia; 0.1 to 0.6 ml/min = very low flow; 0.7 to 0.9 mL/min low flow; 1.0 to 2.0 ml/min = normal flow; and > 2.0 ml/min = high flow.
Study NCT03529500 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva Buffering Capacity
Description: an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC). The saliva/acid solution was shaken in a q 220 vortex tube agitator (Quimis, Diadema, SP, Brazil) for 15 seconds. Next, pH was determined in a portable pH meter (KASVI K39-0014P, Curitiba, PR, Brazil) for the determination of the SBC. The following categories were considered: ≥ 5.5 = very good buffering capacity; 5.4 to 5.0 = good buffering capacity; 4.9 to 4.5 = medium good buffering capacity; 4.4 to 4.0 = low buffering capacity; and ≤ 3.9 very low buffering capacity.
Study NCT02770638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoop Stretcher
Description: Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
Study NCT02770638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Back Spinal board
Description: Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
Study NCT03564990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive, multifaceted approach
Description: A health education module consisting of a lecture and workshop was incorporated into a health-care course.
Study NCT03564990 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional approach
Description: conventional follow-up
Study NCT01513993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring for patients with Congestive Heart Failure
Description: Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms.
Study NCT04381780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recovery Factors
Description: A unique porcine serum based polypeptide nutritional support
Study NCT01582113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
Study NCT01582113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
Study NCT03567408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective PCI
Description: Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
Study NCT03567408 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Selective PCI
Description: Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
Study NCT03567408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
Study NCT03495063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Caffeine
Description: Consumption of 400mg of natural caffeine
Study NCT03495063 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synthetic Caffeine
Description: Consumption of 400mg of synthetic caffeine
Study NCT02869763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g ethanol
Description: 31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.
Study NCT02869763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g ethanol
Description: 63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.
Study NCT02869763 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
Study NCT01428843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FERRISAT
Description: A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
Study NCT01428843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: A single infusion of Glucose 5% solution during inclusion visit
Study NCT04193787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPIC-P
Description: EPIC-P is a brief, bio-behavioral intervention based on the information-motivation-behavioral skills (IMB) model framework, which integrates i) a biomedical component (i.e., PrEP), ii) behavioral components (i.e., drug- and sex-related primary HIV prevention), and iii) mHealth technology (i.e., text messaging PrEP reminders).
Study NCT01227837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo given to patients
Study NCT01227837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omga3
Description: use of omega 3
Study NCT01802905 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: in depth genomic sequencing
Description: Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
Study NCT01460459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a specific frequency of SMBG
Description: Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly
Study NCT02154880 — intervention group
Intervention type: PROCEDURE
Intervention: PFT
Description: Lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD EasyOne Pro system before and after bronchodilator administration.
Study NCT02154880 — intervention group
Intervention type: PROCEDURE
Intervention: lab work
Description: The blood will be processed for serum, plasma, and PBMCS, and a portion stored to be used for future use. A hemoglobin and Carboxyhemoglobin will be done in order to calculate the DLCO.
Study NCT02154880 — intervention group
Intervention type: PROCEDURE
Intervention: 6MWT
Description: The six-minute walk tests are performed in a 100-foot segment of straight hallway marked at 1-foot intervals.
Study NCT02154880 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: TEAL, MMRC and ST. George's Questionnaire will be administered. They are paper questionnaires that inquire about respiratory symptoms, quality of life, smoking history and other health issues
Study NCT03405675 — intervention group
Intervention type: OTHER
Intervention: SLAS 1
Description: NA. Observational study, no interventions administered.
Study NCT03405675 — intervention group
Intervention type: OTHER
Intervention: SLAS 2
Description: NA. Observational study, no interventions administered.
Study NCT03492749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva monitoring
Description: The first objective of this project is to verify the feasibility of using the analysis of salivary concentration of BU during individual adjustments of this drug in the period that precedes HSCT
Study NCT04468945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror box therapy
Description: * Patients in Task-specific mirror box therapy group will receive therapy for 30 min/day, 3 times/week for 6 weeks.~* The patient is seated close to a table a mirror (33\*35 cm) was placed vertically. The involved hand was placed behind the mirror and uninvolved in front of the mirror.~* The subject is asked to transfer small cubes from the middle position to the lateral side, placing pegs in holes and taking them out, turning over paper cards, placing steel needles in holes, stacking blocks, and putting glass on a shelf.~* During the sessions, subjects will be asked to try and do the activity on the unaffected side and asked to do some movement with the paretic hand simultaneously.
Study NCT04468945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive Facilitation Exercise
Description: * The patients in the control group will receive Repetitive Facilitation Exercise for 30 min/day, 3 times/week for 6 weeks.~* Repetitive facilitative techniques were used to elicit movement of the shoulder, elbow, wrist, and fingers in a manner designed to minimize synergistic movements.~* Participants were directed to concentrate on generating movement on the joint being treated while avoiding contraction of non-targeted muscles.~* Therapists provided verbal directions with commands such as bend/straighten or one, two, three.~* Participant efforts were supplemented as necessary to achieve a full range of motion (ROM)
Study NCT04761900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases
Study NCT03457870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction
Description: Dietary advice to follow a 5:2 diet.
Study NCT03457870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing
Description: Asked to chew 1 piece of gum for 10 minutes 3 times a day.
Study NCT03457870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing + Intermittent Energy Restriction
Description: Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
Study NCT02077101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Study NCT02077101 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Study NCT01835691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (ergocalciferol)
Description: 50,000 units once a week for 12 weeks
Study NCT01835691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: 50,000 units once a week for 12 weeks
Study NCT03657602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kyleena Intrauterine System
Description: Participant will be randomly allocated to this intervention
Study NCT03657602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena Intrauterine System
Description: Participant will be randomly allocated to this intervention
Study NCT03389373 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GC Strep Mutans Saliva Sampling
Description: Children who match inclusion criteria will have a saliva sample obtained which will act as a proxy for bacterial levels.
Study NCT02762643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R213
Description: Investigational product is prescribed to all of randomized subjects
Study NCT02762643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Investigational product is prescribed to all of randomized subjects
Study NCT02254772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
Study NCT02254772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
Study NCT02254772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo low-dose radiation therapy to 1 site of disease
Study NCT01202500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reducing treatment to 3 months
Description: The treatment will be stopped after 3 months
Study NCT01202500 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: registered length of treatment
Description: The treatment procedure will follow the actual recommandation
Study NCT00928434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
Study NCT00928434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
Study NCT00928434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
Study NCT02168959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
Study NCT03255369 — intervention group
Intervention type: OTHER
Intervention: Child exposed Zika virus proved
Description: There will be applied Bayley Teste 3rd edition
Study NCT02138565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric by-pass surgery
Study NCT02900352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
Study NCT02900352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00653393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: Tablets, 10 mg, single-dose
Study NCT00653393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parnate
Description: Tablets, 10 mg, single-dose
Study NCT02354287 — intervention group
Intervention type: PROCEDURE
Intervention: Cold forceps polypectomy with pre lift
Description: Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue.
Study NCT03017807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-EGFr Antibody
Description: Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
Study NCT03345641 — intervention group
Intervention type: OTHER
Intervention: describe precocious maternal impressions when confronting the premature birth of her infant
Study NCT03606811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluroscopic guided block
Description: SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.
Study NCT03606811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double modality (ultrasound and fluroscopic) guided block
Description: SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A \& dead lateral)
Study NCT02625701 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
Study NCT02625701 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive fluid therapy
Description: Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
Study NCT04772066 — intervention group
Intervention type: OTHER
Intervention: Measure of medication adherence
Description: Measure of medication adherence
Study NCT00468117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Study NCT00468117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
Study NCT00468117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daclizumab or Basiliximab
Description: Daclizumab or Basiliximab will be used for subsequent transplants.
Study NCT00468117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
Study NCT00468117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic human purified pancreatic islets
Description: 200 ml suspension of allogenic human purified islets
Study NCT01091922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low flavanol cocoa beverage
Description: 23 mg of total flavanols from cocoa
Study NCT01091922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High flavanol cocoa beverage
Description: 495 mg of total flavanols from cocoa
Study NCT01040949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: couple-based counseling for smoking cessation plus self-help smoking cessation guide
Description: Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
Study NCT01040949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guia -a self help smoking cessation guide
Description: A culturally sensitive smoking cessation self help program for Latinos
Study NCT03671070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: IV Low dose Boluses
Study NCT03671070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Traditional management of shock
Description: 1. Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~2. Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~3. Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency.